Drugs.com - Clinical Trials

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

SPRING HOUSE, Pa. (March 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks...

Mar 10, 2025 - 21:58
 0
Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients
SPRING HOUSE, Pa. (March 10, 2025) – Johnson & Johnson (NYSE: JNJ) today announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks...
Read More

Tags:

Previous Article

Gated rental home community in Fort Worth changes hands

Next Article

‘Wasting time’: CDC to study disproven vaccine-autism link

Related Posts

Novo Nordisk Successfully Completes Phase 1b/2a Trial with Subcutaneous Amycretin in People with Overweight or Obesity

Novo Nordisk Successfully Completes Phase 1b/2a Trial w...

Feb 9, 2025  0

Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Datopotamab Deruxtecan Granted Priority Review in the U...

Feb 9, 2025  0

Icotrokinra Results Show Potential to Set a New Standard of Treatment in Plaque Psoriasis

Icotrokinra Results Show Potential to Set a New Standar...

Mar 9, 2025  0